|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Improvements in Quality of Life and Disease-related Symptoms in Phase I Trials of the Selective Oral Epidermal Growth Factor Receptor Tyrosin Kinase Inhibitor ZD1839 in Non-Small Cell Lung Cancer and Other Solid Tumors显示文摘 | LoRusso PM Herbst RS Rischin D | 2003 | Clin Cancer Res2003，9，6： | 1 |
| 2 | Prognostic significance of -misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study显示文摘 | Rischin D Hicks RJ Fisher R | 2006 | J Clin Oncol2006，24，13： | 1 |
| 3 | Phase I safety,pharmacokinetic, and pharmaeodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyroslne kinase inhibitor, in patients with five selected solid tumor types显示文摘 | BASELGA J RISCHIN D RANSON M | 2002 | J Clin Oncol2002，20，21： | 1 |
| 4 | Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinasc inhibitor ZD1839 in non-small cell lung cancer and other solid tumors显示文摘 | LORUSSO PM HERBST RS RISCHIN D | 2003 | Clin Cancer Res2003，9，6： | 1 |
| 5 | Improvements in quality of life and disease-related symptoms in phase Ⅰ trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors显示文摘 | Lo Russo PM Herbst RS Rischin D | 2003 | Clin Cancer Res2003，9，： | 1 |
| 6 | Promising results with chemoradiafion in patients with sinonasal undifferentiated carcinoma显示文摘 | Rischin D Porceddu S Peters L | 2004 | Head Neck2004，26，5： | 1 |
| 7 | Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types 显示文摘 | Baselga J Rischin D Ranson M | 2002 | J Clin Onco2002，20，21： | 1 |
| 8 | Phase Ⅰ safety pharmacokinetic and pharmacodynamic trial of ZD1839,a selective oral epidermal growth factor receptor tyrosine kinase inhibitor,in patients with five selected solid tumor types显示文摘 | Baselga J Rischin D Ranson M | 2002 | J Clin Oncol2002，20，： | 1 |
| 9 | A phase I trial of docetaxel and gemcitabine in patients with advanced cancer 显示文摘 | RISCHIN D BOYER M SMITH J | 2000 | Ann Oncol2000，11，4： | 1 |
| 10 | Improvements in quality of life and disease-ralated symptoms in phase Ⅰ trials of the selective oral epidermal growth factor receptor tyrosinc kinase inhibitor ZD1839 in non-small-cell lung cancer and other solid tumors显示文摘 | Lorusso PM Heebst RS Rischin D | 2003 | Clin Cancer Rest2003，9，6： | 1 |
| 11 | Phase I trial of Cremophor EL with bolus doxorubicin显示文摘 | MILLWARD M J WEBSTER L K RISCHIN D | 1998 | Clin Cancer Res1998，4，： | 1 |
| 12 | A randomised crossover trial of chemotherapy in the home: patient preferences and cost analysis显示文摘 | Rischin D White MA Matthews JP | 2000 | Med J Australia2000，173，3： | 1 |
| 13 | A phase I trial of docetaxel and gemcitabine in patients with advanced cancer 显示文摘 | Rischin D Boyer M smith J | 2000 | Ann Oncol2000，11，4： | 1 |
| 14 | Improvements in quality of life and disease-related symptoms in phase Ⅰ trials of the selective oral epidermal growth factor receptor tyrosine inhibitor ZD1839 in non-small-cell lung cancer and other solid tumors显示文摘 | Lorusso P M Herbst R S Rischin D | 2003 | Clin Cancer Res2003，9，6： | 1 |
| 15 | Phase Ⅰ safety,pharmacokinetic,and pharmacodynamic trial of ZD1839,a selective oral epidermal growth factor receptor tyrosine kinase inhibitor,in patients with five selected solid tumor types显示文摘 | Rischin D Ranson M | 2002 | J Clin Oncol2002，20，21： | 1 |
| 16 | Inprovements in quality of life and disease-related symptoms in phase Ⅰ trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839in non-small cell lung cancer and other solid tumors显示文摘 | Herbst RS Rischin D | 2003 | Clin Cancer Res2003，9，6： | 1 |
| 17 | A randomised crossover trial of chemotherapy in the home: patient preferences and cost analysis显示文摘 | Rischin D White MA Matthews JP | 2000 | Med J Aust2000，173，3： | 1 |
| 18 | A phase I trial of docetaxel and gemcitabine in patients with advanced cancer显示文摘 | Rischin D Boyer M Smith J | 2000 | Ann Oncol2000，11，4： | 1 |
| 19 | Phase Ⅰ safety pharma-cokinetic and pharmacodynamic trial f ZD1839, a selective oral epidermal growth factor receptor tyrosinc kinase inhibitor, in patients with five seleeted solid tumor types 显示文摘 | Baselga J Rischin D Ranson M | 2002 | J Clin Oncol2002，20，： | 1 |
| 20 | Larynx preservation with primary non-surgical treatment for loco-regionally advanced larynx cancer显示文摘 | CORRY J RISCHIN D COTTON S | 2011 | J Medical Imaging Radiation Oncol2011，55，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员